TY - JOUR
T1 - Automated Insulin Delivery Systems
T2 - Hopes and Expectations of Family Members
AU - Garza, Kimberly P.
AU - Jedraszko, Aneta
AU - Weil, Lindsey E.G.
AU - Naranjo, Diana
AU - Barnard, Katharine D.
AU - Laffel, Lori M.B.
AU - Hood, Korey K.
AU - Weissberg-Benchell, Jill
N1 - Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc. 2018.
PY - 2018/3
Y1 - 2018/3
N2 - Background: This study examines the hopes and expectations that children, adolescents, and adults with type 1 diabetes and their families have for new automated insulin delivery systems. The study also aims to examine how the automated insulin delivery system may impact family functioning and individual members' psychosocial adjustment. Methods: Forty-eight semistructured focus groups (n = 195) and 89 individual interviews were conducted with children, adolescents, and adults with type 1 diabetes and parents and partners. Coders reviewed results in key themes most likely to contain references to the family system. Clusters were analyzed using thematic analysis to identify participants' salient hopes and expectations of how new technology may impact family relationships and individual psychosocial functioning. Results: Three main themes emerged for participants' hopes and expectations for implementation of the automated insulin delivery system. First, there is an expectation that this diabetes technology will alleviate diabetes-specific worry and burden for the people with diabetes and other family members. Second, there is also hope that this system may reduce day-to-day stress and, third, improve family relationships. Conclusions: The unique perspective of a broad age group provides insight into how individuals and families creatively address the multiple tasks required in daily diabetes management. Study findings elucidate the very high hopes and expectations held by those managing type 1 diabetes and the impact this new technology may have on family relationships. Awareness of these hopes and expectations is important for developers and clinicians in addressing potential challenges to uptake and to ensure that expectations are set appropriately.
AB - Background: This study examines the hopes and expectations that children, adolescents, and adults with type 1 diabetes and their families have for new automated insulin delivery systems. The study also aims to examine how the automated insulin delivery system may impact family functioning and individual members' psychosocial adjustment. Methods: Forty-eight semistructured focus groups (n = 195) and 89 individual interviews were conducted with children, adolescents, and adults with type 1 diabetes and parents and partners. Coders reviewed results in key themes most likely to contain references to the family system. Clusters were analyzed using thematic analysis to identify participants' salient hopes and expectations of how new technology may impact family relationships and individual psychosocial functioning. Results: Three main themes emerged for participants' hopes and expectations for implementation of the automated insulin delivery system. First, there is an expectation that this diabetes technology will alleviate diabetes-specific worry and burden for the people with diabetes and other family members. Second, there is also hope that this system may reduce day-to-day stress and, third, improve family relationships. Conclusions: The unique perspective of a broad age group provides insight into how individuals and families creatively address the multiple tasks required in daily diabetes management. Study findings elucidate the very high hopes and expectations held by those managing type 1 diabetes and the impact this new technology may have on family relationships. Awareness of these hopes and expectations is important for developers and clinicians in addressing potential challenges to uptake and to ensure that expectations are set appropriately.
KW - Family systems
KW - Technology
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85044473282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044473282&partnerID=8YFLogxK
U2 - 10.1089/dia.2017.0301
DO - 10.1089/dia.2017.0301
M3 - Article
C2 - 29565721
AN - SCOPUS:85044473282
SN - 1520-9156
VL - 20
SP - 222
EP - 228
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 3
ER -